Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Phase Ib Study Of Combination Epigenetic Therapy With 5-Azacitidine and Vorinostat In Patients With Relapsed Or Refractory DLBCL

Tiffany Tang, MD, Peter Martin, MD, Rebecca L. Elstrom, MD, Jia Ruan, MD, PhD, Richard R. Furman, MD, Arcania Garcia, June Greenberg, RN, Amelyn Rodriguez, RN, Alison Bender, PA-C, Jessica Lewis, PA-C, Ari Melnick, MD, Leandro Cerchietti, MD, John P. Leonard, M.D.

Blood (2013) 122 (21): 4339.

https://doi.org/10.1182/blood.V122.21.4339.4339

Published: 2013

Journal Articles

Rituximab Combined with 3 Cycles of High Dose Dexamethasone Improves Response in Patients with Newly-Diagnosed, Persistent, and Chronic Immune Thrombocytopenia (ITP)

Rebecca L. Elstrom, MD, Caroline Seery, BA, Christina Moll, Allison Miller, NP, Julia Gabor, Daniel Maffezzoli, Paul Andrew Basciano, MD, Waleed Ghanima, MD, James B Bussel, MD

Blood (2012) 120 (21): 3345.

https://doi.org/10.1182/blood.V120.21.3345.3345

Published: 2012

Journal Articles

Azacitidine Priming Prior to R-CHOP Is Feasible and Results in Global Demethylation, Restoration of TGF-Beta Pathway, and Improved Chemotherapy Sensitivity in Patients with Newly Diagnosed DLBCL

Rebecca L. Elstrom, MD, Leandro Cerchietti, MD, Peter Martin, MD, Richard R. Furman, MD, ShaoNing Yang, MS, Jia Ruan, MD, PhD, Paul Christos, Morton Coleman, MD, Amelyn Rodriguez, Madhu Mazumdar, Ari Melnick, MD, John P. Leonard, MD

Blood (2012) 120 (21): 3706.

https://doi.org/10.1182/blood.V120.21.3706.3706

Published: 2012

Journal Articles

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy

Rebecca L. Elstrom, MD, John P. Leonard, MD, Paul Christos, Peter Martin, MD, Daniel Lebovic, MD, Joseph Osborne, Stanley J. Goldsmith, June Greenberg, RN, Richard R. Furman, MD, Jia Ruan, MD, PhD, Ryan Putman, Erica Chapman, Madhu Mazumdar, Kent A. Griffith, Morton Coleman, MD, Mark S. Kaminski, MD

Blood (2012) 120 (21): 1636.

https://doi.org/10.1182/blood.V120.21.1636.1636

Published: 2012

Journal Articles

The Novel 2 nd Generation Small Molecule MEK Inhibitor, AZD-6244, Induces Cell Death in Lymphoma Cells Lines, Primary Cells, and in a Human Lymphoma Xenograft Model.

Savita Bhalla, PhD, Ron Gartenhaus, MD, Bojie Dai, PhD, Sheila Prachand, Arindam Mukherjee, Rebecca L Elstrom, MD, Leo I. Gordon, MD, Andrew M. Evens, DO, MSc

Blood (2009) 114 (22): 285.

https://doi.org/10.1182/blood.V114.22.285.285

Published: 2009

Journal Articles

Does FDG-PET/CT Obviate the Need for Standard Diagnostic Contrast-Enhanced CT in Patients with Lymphoma?.

Rebecca L. Elstrom, MD, Richard K.J. Brown, M.D.

Blood (2007) 110 (11): 2329.

https://doi.org/10.1182/blood.V110.11.2329.2329

Published: 2007

Journal Articles

FDG-PET/CT Is Superior to Anatomic Imaging for the Staging and Follow Up of Bony Involvement in Patients with Lymphoma.

Rebecca L. Elstrom, MD, Richard K.J. Brown, M.D.

Blood (2007) 110 (11): 2330.

https://doi.org/10.1182/blood.V110.11.2330.2330

Published: 2007

Journal Articles

Treatment of Post-Transplant Lymphoproliferative Disorder (PTLD) with Rituximab or Chemotherapy: The University of Pennsylvania Experience.

Rebecca L. Elstrom, MD, Charalambos Andreadis, MD, Nicole Aqui, MD, PhD, Donald E. Tsai, MD, PhD

Blood (2005) 106 (11): 936.

https://doi.org/10.1182/blood.V106.11.936.936

Published: 2005

Journal Articles

Impact of FDG-PET Imaging Versus Conventional Staging Modalities on Staging and Treatment Decisions in Large B-Cell, Follicular, and Hodgkin’s Lymphomas.

Ivan Maillard, MDPhD, Rebecca L. Elstrom, MD, Rakesh Kumar, MD, Murat F. Bozkurt, MD, Srikant Sankaran, MD, Liang Guan, MD, Hongming Zhuang, MDPhD, David Herman, Lisa Downs, Abass Alavi, MD, Stephen J. Schuster, MD

Blood (2004) 104 (11): 4565.

https://doi.org/10.1182/blood.V104.11.4565.4565

Published: 2004

NARROW

Phase Ib Study Of Combination Epigenetic Therapy With 5-Azacitidine and Vorinostat In Patients With Relapsed Or Refractory DLBCL

Rituximab Combined with 3 Cycles of High Dose Dexamethasone Improves Response in Patients with Newly-Diagnosed, Persistent, and Chronic Immune Thrombocytopenia (ITP)

Azacitidine Priming Prior to R-CHOP Is Feasible and Results in Global Demethylation, Restoration of TGF-Beta Pathway, and Improved Chemotherapy Sensitivity in Patients with Newly Diagnosed DLBCL

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy

The Novel 2 nd Generation Small Molecule MEK Inhibitor, AZD-6244, Induces Cell Death in Lymphoma Cells Lines, Primary Cells, and in a Human Lymphoma Xenograft Model.

Does FDG-PET/CT Obviate the Need for Standard Diagnostic Contrast-Enhanced CT in Patients with Lymphoma?.

FDG-PET/CT Is Superior to Anatomic Imaging for the Staging and Follow Up of Bony Involvement in Patients with Lymphoma.

Treatment of Post-Transplant Lymphoproliferative Disorder (PTLD) with Rituximab or Chemotherapy: The University of Pennsylvania Experience.

Impact of FDG-PET Imaging Versus Conventional Staging Modalities on Staging and Treatment Decisions in Large B-Cell, Follicular, and Hodgkin’s Lymphomas.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only